Paper Details

  1. Home
  2. Paper Details

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.

Author: BaeSi Hyun, ChangU Im, ChoiJong Young, JangJeong Won, KimChang Wook, KimHee Yeon, KimSeok-Hwan, KwonJung Hyun, LeeHae Lim, LeeSoon Kyu, LeeSung Won, NamHee Chul, NamSoon Woo, RyuJi Eun, SongDo Seon, SongMyeong Jun, SungPil Soo, YangHyun, YangJin Mo, YooSun Hong, YoonSeung Kew

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Direct acting antivirals (DAAs) showed comparable sustained virologic response at week 12 after treatment (SVR12) and safety in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection compared to patients with stage 1 and 2. The effectiveness and safety of DAAs may be related to the treatment duration.
Paper Details　
Original Abstract of the Article :
BACKGROUND/AIMS: To evaluate the effectiveness and safety of direct acting antivirals (DAAs) available in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection in Korea. METHODS: In a retrospective, multicenter cohort study, 362 patients were enrolled from 2015 to 2019. The e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449192/

データ提供：米国国立医学図書館（NLM）

DAAs: A Beacon of Hope for Hepatitis C in Chronic Kidney Disease

This study ventures into the challenging realm of [chronic hepatitis C (HCV)] infection, focusing on its impact on individuals with [chronic kidney disease (CKD)]. The researchers investigated the effectiveness and safety of [direct-acting antivirals (DAAs)] in treating HCV infection across various CKD stages.

DAAs: A Promising Treatment Option Across CKD Stages

The study revealed that DAAs demonstrate consistent efficacy in achieving sustained virologic response (SVR) across different CKD stages, including patients undergoing hemodialysis. This bodes well for the treatment of HCV in CKD patients.

Navigating HCV Treatment in CKD: A Collaborative Approach

While DAAs provide promising treatment options, it's essential to emphasize that careful consideration should be given to the specific regimen and duration of treatment, along with ensuring patient adherence. Collaboration between physicians and patients is crucial for successful outcomes. This underscores the importance of personalized treatment plans for those battling HCV within the complexities of CKD.

Dr.Camel's Conclusion

This study shines a light on the promising future of DAA therapy in treating HCV, even in the challenging landscape of CKD. It's a reminder that even in the vast desert of chronic conditions, there are oases of hope and effective treatments waiting to be discovered.

Date :
  1. Date Completed 2022-09-08
  2. Date Revised 2022-11-20
Further Info :

Pubmed ID

35981893

DOI: Digital Object Identifier

PMC9449192

Related Literature

Article Analysis
・Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.